Signaturefd LLC Sells 924 Shares of Humana Inc. (NYSE:HUM)

Signaturefd LLC trimmed its position in Humana Inc. (NYSE:HUM) by 40.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,367 shares of the insurance provider’s stock after selling 924 shares during the quarter. Signaturefd LLC’s holdings in Humana were worth $347,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FPC Investment Advisory Inc. purchased a new position in shares of Humana in the fourth quarter valued at about $27,000. Centricity Wealth Management LLC purchased a new position in Humana during the 4th quarter valued at about $30,000. LFA Lugano Financial Advisors SA raised its position in Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the last quarter. OFI Invest Asset Management bought a new stake in shares of Humana in the 4th quarter worth approximately $33,000. Finally, Atwood & Palmer Inc. increased its stake in shares of Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after buying an additional 60 shares during the period. 92.38% of the stock is currently owned by institutional investors.

Humana Price Performance

Shares of NYSE HUM opened at $266.33 on Friday. The firm has a market cap of $32.14 billion, a P/E ratio of 26.77, a PEG ratio of 2.05 and a beta of 0.57. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The company has a 50 day moving average of $271.33 and a 200 day moving average of $277.52.

Humana (NYSE:HUM) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, research analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.33%. Humana’s dividend payout ratio is presently 35.58%.

Insider Activity

In other Humana news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.37% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

HUM has been the topic of several recent analyst reports. JPMorgan Chase & Co. cut their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a report on Tuesday, February 18th. Royal Bank of Canada reiterated an “outperform” rating and set a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Morgan Stanley cut their price objective on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. StockNews.com lowered Humana from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $290.00 price target on shares of Humana in a research report on Wednesday, February 12th. Nineteen equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.